By CB2 Insights Inc. on Friday, 17 May 2019
Category: Technology Platforms

CB2 Insights announces new ticker symbol on OTC markets

viewCB2 Insights Inc.

The cannabis data analytics company will continue trading on the OTCQB under the new symbol 'CBIIF'

CB2 Insights is a medical cannabis-focused data firm

() (OTCMKTS:CBIIF) announced Friday that it has changed its OTCQB ticker symbol to “CBIIF.”

The cannabis data analytics company will continue to trade on the Canadian Securities Exchange under the symbol “CBII.”

READ: CB2 Insights strengthens board with new member and appoints chairman

Based in Toronto, is a medical cannabis-focused data firm. The company is busy meeting what it says is significant demand by building a data asset covering the medical cannabis sector by providing predictive analytics tools, data-driven software and services. In addition, it operates 28 cannabis evaluation and education clinics in 12 US states.

CB2 Insights said in a statement Friday that no action is required by shareholders in connection with the ticker symbol change.

Shares of CB2 closed Thursday up 2% to C$0.26 on the Canadian Securities Exchange and were trading at US$0.20 on the OTCQB.  

Contact Angela at [email protected]

Follow her on @AHarmantas

CSE:CBII

Market: CSE
Market Cap: $9.6 m
Follow

View company profile

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CB2 Insights Inc. named herein, including the promotion by the Company of CB2 Insights Inc. in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Most read

Full interview: CB2 Insights announces key partnership with GL Brands for...

CB2 Insights ((CSE: CBII; OTCQB: CBIIF) CEO Prad Sekar joined Steve Darling from our Toronto studio to provide details the will begin a prospective trial with GL Brands that will assess the safety, efficacy and other health measures for patients using Green Lotus’ cannabidiol soft gel capsules...

on 12/17/2019

2 min read

Related Posts